Dr. John Cush RheumNow
2 years 10 months ago
Registration is now open! Early bird pricing is available until 11/30/23. See you there!
https://t.co/zEf9KTXYqX https://t.co/eQTQzgJpVF
Dr. John Cush RheumNow
2 years 10 months ago
The frequency of demyelinating Dz (DD) studied in 2260 #SpA pts, finging 18 DD events (IR 31 per 100K PYs) DD at 20 yrs was higher in axSpA than PsA (1.30 vs 0.13%, p= 0.01). DD risk w/ smoking (HR 2.9), axSpA (8.8) & IBD (5.7) -- NOT TNFi! https://t.co/IVoCxd6H0D https://t.co/FQtHuUWYUx
Dr. John Cush RheumNow
2 years 10 months ago
QD Clinic: Steroid Response for a #PMR Diagnosis
Featuring Dr. Jack Cush (Dallas, TX): Exquisite response to prednisone but other red flags!
https://t.co/DCtcZqG5NE https://t.co/Rs9rfds5w0
Dr. John Cush RheumNow
2 years 10 months ago
TNR: #PMR Diagnosis and Monitoring
Tuesday Night Rheumatology webinar on the diagnosis and monitoring of PMR.
Featuring Panelists, Drs. Claire Owen, Anisha Dua, Stephen Paget and moderated by Jack Cush.
https://t.co/7ewWLAUf4N
@anisha_dua @Rheummd @drceowen https://t.co/GCtYUHBPba
Dr. John Cush RheumNow
2 years 10 months ago
Multinational study of 47 studies of 11,085 #RA pts showed the prevalence of ANXIETY to range from 2.4% to 77%. Variance due to inconsistent, non-standardized self-report measures and clinical thresholds. Common; but how common? https://t.co/elcxjfSI7N https://t.co/iRNeQy4pEk
Dr. John Cush RheumNow
2 years 10 months ago
Network metanalysis review of 65 trials (n=5957) looked at Tx effect in Hand #OA. Whereas oral NSAIDs & glucocorticoids’ NMA were effective compared with placebo; intraarticular steroid & hyaluronate, and HCQ and topical NSAIDs were NOT. https://t.co/8CCkfWd80E https://t.co/jpqlq8Xwgp
Dr. Jack Cush reviews the big PMR reports from this week along with other journal reports from RheumNow.com.
Dr. John Cush RheumNow
2 years 10 months ago
QD Clinic: Difficult #PMR Considerations
Featuring Dr. Sarah Mackie (Leeds, UK) Difficulty weaning prednisone leads to consideration of other confounders and conditions QD Clinics are video vignettes with lessons from the clinic.
https://t.co/H6cZaMperr
@Sarah_L_Mackie https://t.co/WtCX6xfWe3
BE OPTIMAL trial tested the benefits of a dual IL-17 A/F inhibitor, bimekizumab (BKZ), in patients with active psoriatic arthritis and showed superior efficacy over placebo, that was sustained beyond the primary endpoint, from week 16 to 52.
Dr. John Cush RheumNow
2 years 10 months ago
Gout Flare Prophylaxis - Colchicine or NSAIDs?
A new study suggests that colchicine, more so than non-steroidal anti-inflammatory drug (NSAID) prophylaxis, may increase the odds of adverse events, when initiating allopurinol for gout.
https://t.co/MfVvBy0DsD https://t.co/jP5oiAHaBa
Dr. John Cush RheumNow
2 years 10 months ago
Subclinical vasculitis in PMR
For a long time #PMR has been an underinvestigated disease. This is changing with new possibilities to make a more accurate diagnosis with imaging as well as new therapies for treatment resistant disease.
https://t.co/t0BRosgMWt https://t.co/bWZzRidqlm
Dr. John Cush RheumNow
2 years 10 months ago
Subclinical GCA prevalence in newly Dx #PMR ranges from 23 to 29%; best by Vessel imaging or temporal artery Bx. #PMR & GCA share common genetic/pathogenic inflammatory mechanisms & an IL-6 signature; BUT there are differences; further research needed! https://t.co/MhuIs068NG https://t.co/1BeeP3RY0H
Dr. John Cush RheumNow
2 years 10 months ago
GCA pts w/ prior #PMR Dx had 2 fold more Lg vessel dz & signif more vasculitic stenoses. Study of 311 GCA pts, 16% had prior PMR ~ 31 mos before. prior PMR had more LVV (51 vs 25%) & stenosis(18 vs 3%). Prior PMR incr LVV (OR 7.65) https://t.co/1kqtkPnPaz https://t.co/oVs084NfmV

